Ieq Capital LLC Acquires New Stake in Kura Oncology, Inc. $KURA

Ieq Capital LLC bought a new stake in Kura Oncology, Inc. (NASDAQ:KURA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 348,125 shares of the company’s stock, valued at approximately $3,819,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. IFP Advisors Inc grew its holdings in shares of Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after buying an additional 1,284 shares in the last quarter. Royal Bank of Canada boosted its position in Kura Oncology by 7.6% during the fourth quarter. Royal Bank of Canada now owns 19,577 shares of the company’s stock worth $203,000 after acquiring an additional 1,375 shares during the last quarter. Allworth Financial LP grew its stake in Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after acquiring an additional 1,553 shares during the period. Focus Partners Advisor Solutions LLC raised its holdings in Kura Oncology by 7.9% in the 4th quarter. Focus Partners Advisor Solutions LLC now owns 22,889 shares of the company’s stock valued at $238,000 after acquiring an additional 1,682 shares during the last quarter. Finally, ProShare Advisors LLC raised its holdings in Kura Oncology by 10.0% in the 4th quarter. ProShare Advisors LLC now owns 18,572 shares of the company’s stock valued at $193,000 after acquiring an additional 1,692 shares during the last quarter.

Kura Oncology Stock Up 4.3%

Shares of NASDAQ KURA opened at $12.40 on Tuesday. The stock has a market capitalization of $1.10 billion, a PE ratio of -3.68 and a beta of 0.38. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The firm has a fifty day moving average of $10.59 and a 200-day moving average of $9.50. Kura Oncology, Inc. has a 52-week low of $7.36 and a 52-week high of $12.90.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The business had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. On average, analysts anticipate that Kura Oncology, Inc. will post -3.23 EPS for the current year.

Insider Transactions at Kura Oncology

In other news, insider Brian T. Powl sold 4,345 shares of Kura Oncology stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $11.89, for a total value of $51,662.05. Following the transaction, the insider directly owned 169,269 shares of the company’s stock, valued at $2,012,608.41. The trade was a 2.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Teresa Brophy Bair sold 31,487 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $12.63, for a total value of $397,680.81. Following the sale, the insider owned 195,444 shares of the company’s stock, valued at $2,468,457.72. The trade was a 13.88% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 120,761 shares of company stock valued at $1,283,346. 7.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Sanford C. Bernstein set a $24.00 price objective on Kura Oncology in a report on Monday, June 15th. Raymond James Financial set a $24.00 target price on Kura Oncology in a research note on Monday. Morgan Stanley set a $24.00 target price on Kura Oncology in a research report on Monday. Wedbush lifted their price target on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a research note on Monday. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $25.40.

Kura Oncology Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.